BioSpace News Archive

Drug Development

NeoCart’s Revival Continues as FDA Approves Ocugen’s Phase III Trial Design (Updated)

Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.

December 16, 2022
·
3 min read
·
Kate Goodwin
Business

Lilly Plunks Down up to $731M in GPCR Pact with Sosei

Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.

December 16, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Astellas Scores Second CLDN18.2-Positive Gastric Cancer Win (Updated)

Astellas’ zolbetuximab hit the mark in a second late-stage trial in Claudin-18.2-positive gastric cancer.

December 16, 2022
·
3 min read
·
Alex Keown
Business

Synthetic Biology Welcomes Enlaza Therapeutics to the Game

Covalent biologic company Enlaza launches with $61M in seed financing.

December 16, 2022
·
2 min read
·
George Budwell
Business

Henry Schein Makes Investment to Form Strategic Partnership With Biotech Dental Group

Henry Schein, Inc. today announced a definitive agreement with the shareholders of Biotech Dental S.A.S.

December 16, 2022
·
11 min read
CES 2023: OMRON Healthcare Introducing Initiatives to Advance Its Vision of “Going for Zero” -- Elimination of Heart Attack and Stroke

These initiatives include the innovative heart health devices such as Complete, the upper-arm blood pressure monitor with built-in ECG technology, and their global remote patient-monitoring services.

December 16, 2022
·
3 min read
Biotech Bay

Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb

Evotec SE announced that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb.

December 16, 2022
·
4 min read
Alvotech Completes $59.7 Million Private Placement

Alvotech announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds, convertible into new fully paid ordinary shares of Alvotech.

December 16, 2022
·
8 min read
Business

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer

Adagene Inc. today announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma (HCC; liver cancer).

December 16, 2022
·
6 min read
Business

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

Diffusion Pharmaceuticals Inc. today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd.

December 16, 2022
·
6 min read